TearLab Corp fka TEAR

[Wildbilly]

I need a full time interpreter.

[Theo]

Freddy enlightened me...

[Wildbilly]

Short report which covers

thru the end of Nov..

http://shortsqueeze.com/?symbol=tear&submit=Short+Quote%99

http://www.finviz.com/quote.ashx?t=tear

[Theo]

Ahaaaa...makes sense now

[Freddyfred18]

Short position report I'm assuming

[Theo]

15th? What report?

[Wildbilly]

Thanks Steve,

they're still at it a bit today.

I'll be interested to see the 15th's report.

[SSP]

Seasonal shorting is my guess, but to me that only applies to companies that are established, then you can trade cyclical like.
TEAR is still an infant.

[Theo]

Yeah really.... watched it yesterday (in and out all day) and even volume was up a little. Makes ya wonder- do the shorts actually know something or are there so many of them now and nothing's happenin with the stock that they're able to pressure it?

[Wildbilly]

ouch, what happened?

[lewsogge]

Wild shake up there. Entered at 4.08, hope it plays out well.

[Wildbilly]

Happy Thanksgiving folks
I love Thanksgiving turkey...
it's one of the few times you see natural breasts.

Thanksgiving Day, a function which originated in New England two or three centuries ago when those people recognized that they really had something to be thankful for -- annually, not oftener -- if they had succeeded in exterminating their neighbors, the Indians, during the previous twelve months instead of getting exterminated by their neighbors, the Indians. Thanksgiving Day became a habit, for the reason that in the course of time, as the years drifted on, it was perceived that the exterminating had ceased to be mutual and was all on the white man's side, consequently on the Lord's side; hence it was proper to thank the Lord for it and extend the usual annual compliments.

The very fact that a man is thankful implies someone to be thankful to.

Thanksgiving dinners take eighteen hours to prepare. They are consumed in twelve minutes. Half-times take twelve minutes. This is not coincidence.

My mother is such a lousy cook that Thanksgiving at her house is a time of sorrow.

I have strong doubts that the first Thanksgiving even remotely resembled the 'history' I was told in second grade. But considering that (when it comes to holidays) mainstream America's traditions tend to be over-eating, shopping, or getting drunk, I suppose it's a miracle that the concept of giving thanks even surfaces at all.

Gluttony and surfeiting are no proper occasions for thanksgiving.

An optimist is a person who starts a new diet on Thanksgiving Day.

[Theo]

Shorts are not gonna give up

[Wildbilly]

Yeah mon.

[Theo]

purty sweet eh?

[Wildbilly]

TEAR 15 min.,

[SSP]

Whaaaaaaat!!

[Theo]

Giving the shorts some headaches today it appears

[Theo]

TEAR

For the three months ended September 30, 2012, TearLab's net revenues were $1.2 million, an increase of 264% from $333,000 for the same period in 2011 and up 69% sequentially from $716,000 in the previous quarter. A total of 92 orders for TearLab systems were booked in the period. Of those, 77 were through the Company's access programs, six were direct purchases and nine were purchased outside of the U.S.

The Company's net loss for the three months ended September 30, 2012 was approximately $4.6 million, or $0.17 per share. This included approximately $2.0 million, or $0.07 per share, in non-cash expenses related to the revaluation of warrants issued in June 2011 and the issuance of shares for management bonuses. In last year's third quarter, there was an approximate $3.3 million, or $0.16 per share, non-cash gain related to the revaluation of the same warrants and debt conversion that resulted in the Company reporting a profit of $1.1 million, or $0.06 per share ($0.05 on a fully diluted basis).

As of September 30, 2012, the Company had $18.4 million in cash.

[SSP]

Q3 and conference call tomorrow, price creeping up.

[SSP]

short interest for end of October reported, 3,121,916 - up about 300,000 shares, I'm sure it's yet higher taking into account the November trading.

[Wildbilly]

Tempting...

[ktcougar]

Today might have been the day. I added some at $3.85 fwiw.

kt

[Theo]

Still holding- waiting to see if it dips back sub 4 to possibly add.

[SSP]

The short "squeeze trigger" should be from here on upwards!

[SSP]

This is getting shorted based on a seasonal report? This would only hold true if company material events remained the same, TEAR has had many positive advances since then:


Nov 01, 2012 (M2 PRESSWIRE via COMTEX) --
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Tearlab
Corp (NASDAQ:TEAR), DICE HOLDINGS, INC. (NYSE:DHX), Zhongpin Inc
(NASDAQ:HOGS), Sabra Health Care REIT Inc (NASDAQ:SBRA), EV Energy Partners
LP (NASDAQ:EVEP), PPLUS Trust Series GSC-2 (NYSE:PYT) and each have a high
seasonal probability to go Down in the next weeks. By identifying stocks that
are poised to go up or down based on seasonal tendencies, traders can
increase their odds of making money. SqueezeTrigger.com is able to analyze
over 20 years of data in less than 1 second for any stock in the market and
determine if the stock has a long or short seasonal bias, how many trading
days the move is expected to last, the probability of that move and the
percentage move the stock is expected to make based on the seasonal bias. The
technology used to generate these predictions is available for a low monthly
fee at:

http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Down:

Symbol Company Expected Return Odds By The Following Date

TEAR Tearlab Corp -22.84% 85.71% (6 of 7) Friday, December 14th 2012

DHX DICE HOLDINGS, INC. -9.49% 100.00% (5 of 5) Friday, November 16th 2012

HOGS Zhongpin Inc -12.97% 66.67% (4 of 6) Wednesday, November 21st 2012

SBRA Sabra Health Care REIT Inc -9.69% 100.00% (10 of 10) Tuesday, November
20th 2012

EVEP EV Energy Partners LP -1.85% 100.00% (6 of 6) Friday, November 2nd 2012

PYT PPLUS Trust Series GSC-2 -2.15% 87.50% (7 of 8) Monday, November 12th
2012

Tearlab Corp (NASDAQ:TEAR) - TearLab Corporation is an ophthalmic device
company and engages in commercializing a proprietary in vitro diagnostic tear
testing platform, the TearLab test for dry eye disease. Its TearLab
Osmolarity System enables eye care practitioners to test for highly sensitive
and specific biomarkers using nanoliters of tear film at the point-of-care.
The companys TearLab Osmolarity System consists of the TearLab disposable, a
single-use microfluidic labcard; the TearLab pen, a hand-held device, which
interfaces with the TearLab disposable; and the TearLab reader, a small
desktop unit that allows for the docking of the TearLab disposable and the
TearLab pen, as well as provides a quantitative reading for the operator. It
sells its products through distributors in Europe, Asia, and North America.
TearLab Corporation was formerly known as OccuLogix, Inc. and changed its
name to TearLab Corporation on May 17, 2010. TearLab Corporation was founded
in 1996 and is headquartered in San Diego, California..

[SSP]

TearLab Corporation - Common Stock
Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover

10/15/2012 	2,823,686 	27.02 	252,178 	11.20 
 09/28/2012 	2,223,098 	16.27 	117,432 	18.93 
 09/14/2012 	1,911,943 	9.44 	109,581 	17.45 
 08/31/2012 	1,747,102 	(1.30) 	109,816 	15.91 
 08/15/2012 	1,770,086 	5.92 	77,012 	22.98 
 07/31/2012 	1,671,222 	5.59 	100,903 	16.56 
 07/13/2012 	1,582,731 	(4.32) 	100,604 	15.73 
 06/29/2012 	1,654,187 	(11.33) 	95,436 	17.33 
 06/15/2012 	1,865,520 	(0.92) 	84,802 	22.00 
 05/31/2012 	1,882,920 	(2.67) 	175,370 	10.74 
 05/15/2012 	1,934,617 	14.37 	188,137 	10.28 
 04/30/2012 	1,691,541 	5.67 	281,063 	6.02 
 04/13/2012 	1,600,743 	65.63 	455,667 	3.51 
 03/30/2012 	966,449 	247.77 	377,247 	2.56 
 03/15/2012 	277,901 	65.44 	481,676 	1.00 
 02/29/2012 	167,977 	151.19 	93,115 	1.80 
 02/15/2012 	66,872 	(73.12) 	43,227 	1.55

[beach_trades]

Canaccord Genuity Remains Positive on TearLab (TEAR)

October 15, 2012 9:20 AM EDT

In a note, Canaccord Genuity pointed out that TearLabs (Nasdaq: TEAR) has expanded its total company headcount to 47 employees in a matter of several month. Analysts remain positive on the stock and think the company will rapidly grow business.

Canaccord Genuity has a Buy rating on TearLabs and a price target of $6.00 on TearLabs.

http://finviz.com/quote.ashx?t=TEAR&ty=c&ta=0&p=d

[spottrader]

TEAR wants to riiiiiiiiiiiiiip. Just let it goooooooooooo!

[BlueBookStockGuide]

SIA-Chart on TEAR : Very Bullish : Besides having a superman show up, which happens when the stock goes 5% above its 100 day moving average. We also have a super cross show up which means that the 50 day moving average has broken above the 100 day moving average, which is also very bullish and means that buyers are coming in big time.

[ListenToMe]

akrx would be a good candidate......

[Wildbilly]

Who do you have in mind?

[ListenToMe]

Watch for a buyout!

[Wildbilly]

LOL...

[beach_trades]

TEAR Chart-Break out any day, 1.7 million trapped short

http://finviz.com/quote.ashx?t=tear&ty=c&ta=1&p=d

http://online.wsj.com/mdc/public/page/2_3062-shtnasdaq_T-listing.html

[Wildbilly]

My mother had dry eye disease
before she passed and we were directed to the institute here
in Cinti. in 2009. It was a virtual Taj Mahal then, a huge
and growing issue with boomers back then. This is going to be
major biggly, growing and much needed.

[ListenToMe]

Nice, Nice.... VERY NICE :)

[Wildbilly]

TearLab to Participate in Craig-Hallum's 3rd Annual Alpha Select Conference.
3.9 0.05 (1.30%) @ 4:31PM

TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today that its Vice President of Clinical Affairs & Professional Development, David C Eldridge, OD, FAAO, will present an update on the Company's business at the 3rd Annual Craig-Hallum Alpha Select Conference on Thursday, September 27, 2012 at 2:10 p.m. Eastern Time. The conference will be held at the Sentry Centers, New York.

Dr. Eldridge's presentation will be webcast live and archived for approximately 90 days on the Company's website at http://www.tearlab.com under the "Webcasts" tab in the Investors section.

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

CONTACT: Stephen Kilmer
647.872.4849
[e-mail]

[SSP]

classic, love that movie.

[Wildbilly]

Randolph Duke: Money isn't everything, Mortimer.

Mortimer Duke: Oh, grow up.

[SSP]

[Wildbilly]

Lol, I'm feeling evil all of a sudden.

[SSP]

INDEED!

[Wildbilly]

Ha ha holy cow!

That's got to be some kind of record.

All because they can't read between the lines of a start-up?

Oh boy.

[SSP]

Exactly, I just edited my previous post to show the short position increase.

[Wildbilly]

There are some stubborn shorts here too,

I'll look forward to that day. :-o

[SSP]

All we need now is news releases on major deals (which will come), and this will cause some short covering spurred with new buying.

Short interest has climbed quite a bit this year,

TearLab Corporation - Common Stock 
 Settlement Date 	Short Interest 	Percent Change 	Average Daily Share Volume 	Days to Cover 
 08/31/2012 	1,747,102 	(1.30) 	109,816 	15.91 
 08/15/2012 	1,770,086 	5.92 	77,012 	22.98 
 07/31/2012 	1,671,222 	5.59 	100,903 	16.56 
 07/13/2012 	1,582,731 	(4.32) 	100,604 	15.73 
 06/29/2012 	1,654,187 	(11.33) 	95,436 	17.33 
 06/15/2012 	1,865,520 	(0.92) 	84,802 	22.00 
 05/31/2012 	1,882,920 	(2.67) 	175,370 	10.74 
 05/15/2012 	1,934,617 	14.37 	188,137 	10.28 
 04/30/2012 	1,691,541 	5.67 	281,063 	6.02 
 04/13/2012 	1,600,743 	65.63 	455,667 	3.51 
 03/30/2012 	966,449 	247.77 	377,247 	2.56 
 03/15/2012 	277,901 	65.44 	481,676 	1.00 
 02/29/2012 	167,977 	151.19 	93,115 	1.80 
 02/15/2012 	66,872 	(73.12) 	43,227 	1.55

[Wildbilly]

Thank goodness, I'm up pretty decent

now for getting in so late.

I wonder why Ihub didn't post that to the board,

yet sent it to my mail?

[SSP]

Interest in shares this morning, nice gain so far.

[Wildbilly]

Prospectus filed pursuant to Rule 424(b)(3) (424B3)
Date : 09/19/2012 @ 9:00AM
Source : Edgar (US Regulatory)
Stock : Tearlab Corp. (MM) (TEAR)
Quote : 3.8792 0.1992 (5.41%) @ 11:38AM

- Prospectus filed pursuant to Rule 424(b)(3) (424B3)
Print
Alert

Filed Pursuant to Rule 424(b)(3) and Rule 424(c)
Registration No. 333-175861

PROSPECTUS SUPPLEMENT NO. 8
(to Prospectus dated April 10, 2012)

7,692,308 Shares
Common Stock



This Prospectus Supplement No. 8 supplements the prospectus dated April 10, 2012 or the prospectus, which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-175861). This prospectus supplement is being filed to update, amend and supplement the information included or incorporated by reference in the prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 8, 2012 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement.

The prospectus and this prospectus supplement relate to the disposition from time to time by the selling stockholders identified in the prospectus, or their permitted transferees or other successors-in-interest, of an aggregate of 7,692,308 shares of our common stock, including shares issuable upon the exercise of warrants to purchase our common stock. We are not selling any common stock under the prospectus and this prospectus supplement, and will not receive any of the proceeds from the sale of shares by the selling stockholders.

This prospectus supplement should be read in conjunction with the prospectus, which is to be delivered with this prospectus supplement. This prospectus supplement updates, amends and supplements the information included or incorporated by reference in the prospectus. If there is any inconsistency between the information in the prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common stock is listed on The NASDAQ Capital Market under the symbol “TEAR,” and on the Toronto Stock Exchange under the symbol “TLB.” The last reported sale price of our common stock on The NASDAQ Capital Market on August 7, 2012 was $3.59 per share.

Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” beginning on page 5 of the prospectus, and under similar headings in any amendments or supplements to the prospectus, and “Part II — Item 1A — Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.


The date of this prospectus supplement is August 8, 2012





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

September 16, 2012


TEARLAB CORPORATION
(Exact name of registrant as specified in its charter)

Delaware

000-51030

59-343-4771
(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

7360 Carroll Rd, Ste 200
San Diego, CA 92121
(Address of principal executive offices, including zip code)

[phone]
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 16, 2012, the compensation committee, or the Committee, of the board of directors of TearLab Corporation, or the Company, approved the payment of previously announced milestone bonuses based on the receipt of CLIA waiver categorization for the TearLab TM Osmolarity System, or the CLIA Bonus, to certain members of the Company’s management team.

The CLIA Bonus will be paid in the form of restricted stock units, or RSUs, issued pursuant to the Company’s 2002 Stock Option Plan, as amended. A total of 440,000 RSUs were approved, of which 80,000 will be issued to Elias Vamvakas, Chairman of the board of directors and Chief Executive Officer, and 40,000 will be issued to each of Bill Dumencu, Chief Financial Officer, Robert Walder, Vice President, Operations, and Stephen Zmina, Vice President, Manufacturing and Engineering. The number of RSUs issued to each recipient will be reduced by an amount, based on the market price of the Company’s common stock, to cover withholding taxes applicable to each award. Each RSU will be fully vested at the date of grant and the underlying shares of stock will be issued upon the first to occur of (i) termination of the recipient’s service to the Company; (ii) a change in control of the Company; (iii) the death of the recipient; (4) the disability of the recipient; or (5) September 17, 2012.





SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


TEARLAB CORPORATION


By:

/s/ William G. Dumencu


William G. Dumencu


Chief Financial Officer